Selectivity of SSRIs: Individualising patient care through rational treatment choices

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue SUPPL. 1, 2004, Pages 3-10

  Stahl, Stephen M ^a  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

Author keywords

5 HT receptor; Anxiety disorders; Binding sites; Cytochrome P450; Depression; Selective serotonin reuptake inhibitor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CITALOPRAM; CYTOCHROME P450; DOPAMINE; DOPAMINE RECEPTOR; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HISTAMINE RECEPTOR; MIANSERIN; MIRTAZAPINE; MUSCARINIC RECEPTOR; NEFAZODONE; NITRIC OXIDE SYNTHASE; PAROXETINE; PROTON PUMP INHIBITOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA OPIATE RECEPTOR; THEOPHYLLINE; TRAZODONE;

AGITATION; AKINESIA; ANXIETY; ANXIETY DISORDER; APATHY; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIZZINESS; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MELANCHOLIA; NAUSEA; PRIORITY JOURNAL; SEDATION; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TRANQUILIZING ACTIVITY; TREMOR;

EID: 6044270573     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005487     Document Type: Conference Paper

References (82)

1. Fichter M, Leibl K, Rief W et al (1991) Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 24: 107.
2. Zohar J, Wetenberg H (2000) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin re-uptake inhibitors. Acta Psychiatr Scand Suppl 403: 39-49.
3. Pigott T, Seay S (1999) A review of the efficacy of selective serotonin re-uptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatr 60: 101-6.
4. Dimmock P, Wyatt K, Jones P et al (2000) Efficacy of selective serotonin re-uptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356: 1131-6.
5. van der Linden G, Stein D, van Balkom A (2000) The efficacy of the selective serotonin re-uptake inhibitors for social anxiety disorder (social phobia); a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15: 515-23.
6. Clemmesen L (1988) Anticholinergic side-effects of antidepressants: studies of the inhibition of salivation. Acta Psychiatr Scand Suppl 345: 90-3.
7. Beaumont G (1988) Adverse effects of tricyclic and non-tricyclic antidepressants. Int Clin Psychopharmacol 3 (Suppl. 2): 55-61.
8. Feighner J, Boyer W (1996) Selective serotonin re-uptake inhibitors, Advances in Basic Research and Clinical Practice (2nd Edn). Wiley, Chichester.
9. Stahl S (1996) Essential Psychopharmacology. New York: Cambridge University Press.
10. Barker E, Blakely R (1995) Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 321-34.
11. Stahl S (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutics effects and side-effects. J Affect Disord 51: 215-35.
12. Stahl S (2000) Essential psychopharmacology (2nd Edn) Cambridge University Press, New York.
13. Brown S, van Praag H (1991) The role of serotonin in psychiatric disorders. Brunner/Mazel, New York.
14. Cowen P (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 159: 7-14.
15. Glennon R, Dukat M (1995) Serotonin receptor subtypes. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 415-30.
16. Kunovac J, Stahl S (1995) Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 7: 55-68.
17. Shih J, Chen K, Gallaher T (1995) Molecular biology of serotonin receptors: a basis for understanding and addressing brain function. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 407-14.
18. Jacobs B, Fornal C (1995) Serotonin and behavior: a general hypothesis. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 461-70.
19. Langer S, Brunello N, Racagni G, Mendlewicz J (1992) Serotonin receptor subtypes: pharmacological significance and clinical implications. Karger, Basel.
20. Frazer A, Maayani S, Wolfe B (1990) Subtypes of receptors for serotonin. Annu Rev Pharmacol Toxicol 30: 307-48.
21. Hoyer D, Clarke D, Fozard J et al (1994) International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157-203.
22. Thase M, Feighner J, Lydiard R (2001) Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 62: 683-7.
23. Benfield P, Ward A (1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 313-4.
24. Benfield P, Heel R, Lewis S (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 482-508.
25. Dechant K, Clissold S (1991) Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 41: 225-53.
26. Murdoch D, McTavish D (1992) Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44: 604-24.
27. Owens M, Knight D, Nemeroff C (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345-50.
28. Sánchez C, Larsen A, Brennum L et al (2002) Escitalopram, an extremely selective serotonin re-uptake inhibitor. Int J Neuropsychopharmacol 59 (Suppl. 1): S66.
29. Schmidt K, Nolte-Zenker B, Patzer J et al (2001) Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 34: 66-72.
30. Stahl S (1998) Using secondary binding properties to select a not so selective serotonin re-uptake inhibitor. J Clin Psychiatry 59: 642-3.
31. Judge R, Plewes J, Kumar V et al (2000) Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials. J Clin Psychpharmacol 20: 666-72.
32. Stokes P, Holtz A (1997) Fluoxetine Tenth Anniversary Update: The Progress Continues. Clin Ther 19: 1135-50.
33. Tulloch I, Lowther S, Crompton M et al (1995) Pharmacological differences between selective serotonin re-uptake inhibitors: interaction with 5-HT and sigma binding sites in human brain in vitro. Eur Neuropsychopharmacol 5 (Suppl. 3): 281.
34. Bolden-Watson C, Richelson E (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023-9.
35. Edwards J, Anderson I (1999) Systematic review and guide to selection of selective serotonin re-uptake inhibitors. Drugs 57: 507-33.
36. Fava M, Rosenbaum J, Hoog S et al (2000) Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59: 119-26.
37. Sechter D, Troy S, Paternetti S, Boyer P (1999) A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14: 41-8.
38. Sogaard J, Lane R, Latimer P et al (1999) A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 13: 406-14.
39. Finkel S, Richter E, Clary C (1999) Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 11: 85-99.
40. Newhouse P (1996) Use of serotonin selective re-uptake inhibitors in geriatric depression. J Clin Psychiatry 57 (Suppl. 5): 12-22.
41. Aguglia E, Casacchia M, Cassano G et al (1993) Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197-202.
42. Flament MF, Lane RM, Zhu R, Ying Z (1999) Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 14: 259-75.
43. Zimmerman M, McDemut W, Mattia J (2000) Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 157: 1337-40.
44. Rouillon F (1999) Anxiety with depression: a treatment need. Eur Neuropsychopharmacol 9: S87-92.
45. Boerner R, Möller H (1999) The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 32: 119-26.
46. Joubert A, Stein D (1999) Citalopram and anxiety disorders. Rev Contemp Pharmacother 10: 79-123.
47. Tye N, Iversen S, Green A (1979) The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 18: 689-95.
48. Stein L, Wise C, Belluzi J (1975) Effects of benzodiazepines on central serotonergic mechanisms. In: Costa E, Greengard P (eds) Mechansim of benzodiazepines. New York: Raven Press: 29-44.
49. Barrett J, Vanover K (1993) 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology (Berlin) 112: 1-12.
50. Schreiber R, Melon C, De Vry J (1998) The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin re-uptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berlin) 135: 383-91.
51. Sánchez C, Meier E (1997) Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berlin) 129: 197-205.
52. Ballenger J (1996) Selective serotonin re-uptake inhibitors in panic disorder. In: Feighner J, Boyer W (eds) Selective serotonin re-uptake inhibitors, Advances in Basic Research and Clinical practice, 2nd Edn. Wiley: Chichester: 155-78.
53. Pollock BG, Mulsant BH, Nebes R et al (1998) Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 155: 1110-2.
54. Dunbar G (1989) An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand Suppl 80 (350): 135-7.
55. Kiev A, Feiger A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146-52.
56. Aberg-Wistedt A, Agren H, Ekselius L et al (2000) Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20: 645-52.
57. Narita H, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin re-uptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307: 117-9.
58. Su T, Hayashi T (2003) Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10: 2073-80.
59. Zanardi R, Franchini L, Gasperini M et al (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153: 1631-3.
60. Gatti F, Bellini L, Gasperini M et al (1996) Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 153: 414-6.
61. Sánchez C, Bergqvist P, Brennum L et al (2003) Escitalopram, the S-(+) enantiomer of citalopram is a selective serotonin re-uptake inhibitor with potent effects of animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167: 353-62.
62. Drewes P, Thijssen I, Mengel H (2001) A single-dose cross-over pharmacokinetic study comparing racemic citalopram (40mg) with the S-enantiomer of citalopram (escitalopram, 20mg) in healthy male volunteers. Poster presented at the 41st Annual Meeting of the New Clinical Data Evaluation Unit (NCDEU), Phoenix, AZ, USA, 29 May-1 June 2001. Abstract available at http://www.nimh.nih. gov/ncdeu/abstracts2001/ncdeu2045.csm.
63. Wade A (2002) Long-term treatment of depression with escitalopram is safe and well-tolerated. Int J Neuropsychopharmacol 5 (Suppl 1): S146.
64. Boyer W, Feighner J (1996) Other uses of selective serotonin re-uptake inhibitors in psychiatry. In Feighner J, Boyer W, Selective serotonin re-uptake inhibitors: advances in basic research and clinical practice (2nd Edn). Wiley: Chichester: 291-314.
65. Stein D, Hollander E (1994) Sexual dysfunction associated with the drug treatment of psychiatric disoders. CNS Drugs 2: 78-86.
66. Montejo-Gonzalez A, Liorca G, Izquierdo J et al (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176-94.
67. Angulo J, Peiro C, Sanchez-Ferrer C et al (2001) Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br J Pharmacol 134: 1190-4.
68. Balon R (1996) Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther 22: 85-96.
69. Atmaca M, Kuloglu M, Tezcan E, Semercioz A (2002) The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 14: 502-5.
70. Waldinger M, Zwinderman A, Olivier B (2001) SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 21: 556-60.
71. Harvey A, Preskorn S (1996) Cytochrome P450 enzymes: interpretations of their interactions with selective serotonin re-uptake inhibitors. Part 1. J Clin Psychopharmacol 16: 273-85.
72. Wang J, Liu Z, Wang W et al (2001) Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70: 42-7.
73. Keppel Hesselink J, Sambunaris A (1995) Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 7: 41-54.
74. Cliffe I, Fletcher A (1993) Advances in 5-HT1A antagonist research. Drugs Future 18: 631-42.
75. Dubovsky S (1994) Beyond the serotonin re-uptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 55: 34-44.
76. Stahl S (1992) Serotonin 1A receptors in depression and anxiety. New York, Raven Press: 55-82.
77. Bersani G, Grispini A, Marini S et al (1990) 5-HT2 antagonist ritanserin in neuroleptic induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500-6.
78. Leysen J (1992) 5-HT2 receptors: location, pharmacological pathological and physiological role. In: Langer S, Brunello N, Racagni G, Mendlewicz J (eds) Serotonin receptor subtypes: pharmacological significance and clinical implications. Basel: Karger: 31-44.
79. Trickelbank M (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 127-9.
80. Bunce K, Tyers M, Beranek P (1991) Clinical evaluation of 5-HT3 receptor agonists as antiemetics. Trends Pharmacol Sci 12: 46-8.
81. Levitt M, Warr D, Yelle L (1993) Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemptherapy of breast cancer with cyclophosphamide, methotrexate and flurouracil. New Engl J Med 328: 1081-4.
82. Waugh J, Goa K (2003) Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17: 985-92.